Smoking
Conditions
Keywords
Smoking cessation, Bupropion
Brief summary
Bupropion has different effects on D2 dopamine receptors according to genotype.
Detailed description
Open, one arm, single sequence, 2-period, study stratified into 2 DRD2 genotype groups For subjects who volunteer to cease smoking, genotypes are investigated. Twelve subjects are enrolled (6 - DRD2 Taq1A1 allele, 6 - DRD2 Taq1A2 homozygotes). Subjects receive baseline raclopride PET (High Specific Activity, Low Specific Activity). * Period 1 Subjects receive 150 mg of bupropion SR every day. After 1 week of medication, pharmacokinetic and PET studies are performed. * Period 2 Subjects receive 150 mg of bupropion SR twice a day. After 1 week of medication, pharmacokinetic and PET studies are performed.
Interventions
DRUGBupropion
bupropion
Sponsors
Ministry of Health, Welfare and Family Affairs
Korea National Enterprise for Clinical Trials
Seoul National University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Active smoker (more than 10 cigarettes per day for the past 2 years)
Exclusion criteria
* Medical or psychiatric co-morbidity * Hypersensitive to bupropion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dopamine receptor occupancy | 1 week |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters of bupropion and hydroxybupropion | 1 week |
Countries
South Korea
Outcome results
None listed